The preclinical development of regorafenib for the treatment of colorectal cancer

Regorafenib

(2014) Daniel J. Crona et al.   ANNALS OF PHARMACOTHERAPY

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

(2013) B. Schultheis et al.   ANNALS OF ONCOLOGY

Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer

(2013) Adriana Zámečníkova   Expert Opinion on Drug Discovery

Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics

(2013) Yu Sunakawa et al.   INVESTIGATIONAL NEW DRUGS

Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model

(2013) L. Abou-Elkacem et al.   MOLECULAR CANCER THERAPEUTICS

MEK in cancer and cancer therapy

(2013) Cindy Neuzillet et al.   PHARMACOLOGY & THERAPEUTICS

Regorafenib Effects on Human Colon Carcinoma Xenografts Monitored by Dynamic Contrast-Enhanced Computed Tomography with Immunohistochemical Validation

(2013) Clemens C. Cyran et al.   PLoS One

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

(2012) D Strumberg et al.   BRITISH JOURNAL OF CANCER

A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

(2012) K. Mross et al.   CLINICAL CANCER RESEARCH

Regorafenib for cancer

(2012) Dirk Strumberg et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Transformation ofin vitrotools for kinase profiling: keeping an eye over the off-target liabilities

(2011) Kun Bi et al.   Expert Opinion on Drug Discovery

BRAF Inactivation Drives Aneuploidy by Deregulating CRAF

(2010) T. Kamata et al.   CANCER RESEARCH

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

Molecular Basis of Colorectal Cancer

(2009) Sanford D. Markowitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS